AmgenCHIX:AMGD 90 3-Year EBITDA Growth Rate is 11.50% as of Mar. 2026, which is 25% below its 10-year median of 15.35. GuruFocus rates CHIX:AMGD with a GF Score™ of 90/100 and a GF Value™ of €325.97 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 813 Drug Manufacturers companies, Amgen ranks better than 56.09% on this metric.
During the past 12 months, Amgen's average EBITDA Per Share Growth Rate was 8.90% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 11.50% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 7.80% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 6.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Amgen was 386.60% per year. The lowest was 0.60% per year. And the median was 15.35% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Amgen 3-Year EBITDA Growth Rate Related Terms
CHIX:AMGD vs GILD, PFE, BMY: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - General subindustry, Amgen's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amgen 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amgen's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Amgen's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 11.50% mean?
Amgen (CHIX:AMGD) has a 3-Year EBITDA Growth Rate of 11.50% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Amgen and its competitors. This is 25% below median its historical median of 15.35. Over the past decade, Amgen's 3-Year EBITDA Growth Rate has ranged from 0.60 to 386.60. According to the industry distribution chart, Amgen ranks #357 out of 813 companies in the Drug Manufacturers industry, placing it in the top 43.9%.
Is Amgen's 3-Year EBITDA Growth Rate too high?
Amgen's current 3-Year EBITDA Growth Rate of 11.50% is 25% below median its 10-year median of 15.35. Over the past 10 years, this metric has ranged from a low of 0.60 to a high of 386.60. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Amgen's value of 11.50% is 29.2% above this industry median. Based on the distribution chart, Amgen ranks #357 out of 813 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Amgen has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amgen's 3-Year EBITDA Growth Rate compare to GILD and PFE?
According to the Drug Manufacturers industry distribution chart, Amgen ranks #357 out of 813 companies for 3-Year EBITDA Growth Rate. This puts Amgen in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.90. Amgen's value of 11.50% is 29.2% above this benchmark. Historically, Amgen's own 3-Year EBITDA Growth Rate has ranged from 0.60 to 386.60 over the past decade. While the company's 10-year median is 15.35 vs. the industry median of 8.90, Amgen has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amgen's current 3-Year EBITDA Growth Rate of 11.50% is 29.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Amgen and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amgen's current 3-Year EBITDA Growth Rate is 11.50%, which is 25% below median its own 10-year median of 15.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amgen stock overvalued right now?
Based on GuruFocus' analysis, Amgen (CHIX:AMGD) is currently considered Modestly Undervalued. The stock's GF Value™ is €325.97, compared to a current price of €285.00 — trading 12.6% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 11.50%, which is 25% below median its 10-year median of 15.35 and 29.2% above the Drug Manufacturers industry median of 8.90. Amgen's overall GF Score™ is 90/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Amgen (CHIX:AMGD), the current 3-Year EBITDA Growth Rate is 11.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amgen (CHIX:AMGD) Overvalued in 2026?
Based on GuruFocus' analysis, Amgen stock appears to be undervalued.
The current stock price of €285.00 is trading 12.6% below its estimated GF Value™ of €325.97.
GuruFocus considers Amgen to be Modestly Undervalued.
Key valuation signals for CHIX:AMGD:
3-Year EBITDA Growth Rate: 11.50% (25% below median its 10-year median of 15.35)
GF Value™: €325.97 vs. price of €285.00 (12.6% below fair value)
Industry Position: 29.2% above the Drug Manufacturers median (#357 of 813)
No single metric tells the full story. See the CHIX:AMGD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
90GF Score
Get the complete analysis for CHIX:AMGD
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:AMGD has been successfully added to your 